A single-vendor 340B TPA platform is one organization and one system running your 340B third-party administrator services end to end: patient eligibility, claims qualification, contract pharmacy administration, reporting, and audit support.
Instead of stitching together a TPA, split-billing software, a referral capture service, and a consultant to reconcile them, you work from one data layer with one team.
That's the definition. Here's why it matters. The 340B Program was built so safety-net providers could stretch scarce resources further, and those savings are yours by design. Capturing every compliant dollar available to you shouldn't depend on how many vendors you can manage. Yet a TPA on its own rarely gets you all of it.
"Single platform" is also a common claim among 340B TPA vendors, so the real question is what the platform is unified around. One login is not the same as one program.
The 340B Program lets eligible providers "stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services." Covered entities include community health centers and other federal grantees, plus six types of 340B-qualified hospitals: disproportionate share, sole community, rural referral centers, critical access, children's, and free-standing cancer hospitals.
A TPA handles the program's operational requirements in exchange for fees. University of Minnesota researchers who mapped the market grouped TPA services into seven categories: enrollment, auditing, revenue capture, inventory management, referral management, 340B ESP assistance, and patient discount cards.
Here's the part that matters most when you're choosing one: the TPA does the work, but the liability stays with you. HRSA's 2010 contract pharmacy guidance says using a contract pharmacy "does not lessen" a covered entity's duty to run its program in compliance, and HRSA states the entity "remains responsible" for guarding against diversion and duplicate discounts. Outsourcing the administration doesn't outsource the audit.
Because for years, no single TPA did everything. The same University of Minnesota study identified 48 TPA firms. Of those, only nine listed referral management among their services, and only nine offered 340B ESP assistance. Even among software-based TPAs, just 45% offered a referral capture module. If you needed either, you added a vendor.
Pharmacy structure compounds it. In a 2022 NACHC survey, 56% of responding health centers operated an in-house pharmacy and 86% used contract pharmacies. Running both means two dispensing channels that still have to reconcile to one 340B program.
And the job keeps growing. As of late September 2026, at least 16 manufacturers require claims data for in-house pharmacy dispenses. HRSA's rebate pilot is scheduled to start January 1, 2027, though hospital groups sued on October 9, 2026 to block that start. And CMS opened its Medicare Part D 340B repository for voluntary submissions in October 2026. Each one is another file, another deadline, and another place a claim can fall out.
Each vendor may do its piece well. The drawbacks live in the handoffs between them.
You keep a different rulebook for every vendor. Each TPA applies its own matching logic, encounter windows, and blocked-NDC lists. When a prescriber's claim qualifies at one pharmacy but not another, someone on your team has to dig through two systems to find out why. Small differences in eligibility logic add up, for compliance and for savings.
Vendors can compete for the same spot. Some manufacturers limit a covered entity to a single contract pharmacy designation. If two vendors each want their pharmacy in that spot, who decides, and how would you know who's right? As NuvemRx's Carrie Galvan, CPhT, MBAn, puts it in her 340B Report article:
"When all your data is in one place, the question stops being which vendor wins and becomes what's best for your clinic as a whole."
Reconciliation multiplies. HRSA recommends quarterly internal audits and annual independent audits of every contract pharmacy you use, plus written procedures for reconciling dispensing, purchasing, and billing records. Every additional vendor is another data source to pull into that reconciliation.
Audit exposure is real. In Bluesight's analysis of 115 finalized FY2025 HRSA audits, 49% of covered entities received adverse findings. Incorrect OPAIS records appeared in three quarters of those, and half of the entities with findings were required to repay manufacturers.
Fees stack. A Senate HELP Committee report found that one chain-owned TPA charged a first-year administrative fee of the greater of $4 or 10% of the prescription reimbursement minus the 340B ceiling price, rising to 14% by year three. Add a second or third vendor and total program cost gets hard to see.
Referral prescriptions fall between systems. A referral capture opportunity is an eligible 340B script for your patient, written by an outside specialist, filled at a pharmacy you don't control. Nothing about that transaction starts in your data. When referral capture lives apart from your TPA, the question your CFO asks ("what did our program capture, and where did we leave dollars?") belongs to no one.
Use this as a standard you can hold any partner to, including us:
One eligibility engine across every channel. Contract pharmacy, entity-owned pharmacy, and referral claims qualified by the same rules, in the same system. Test: how many places does your eligibility logic live? The answer should be one.
One view of the whole program. Chain, independent, in-house, and referral volume in a single data layer, feeding every reporting destination from the same source.
Referral capture connected to administration, not bolted beside it. Referral claims should draw on the same claims data as the rest of your program, not a separate feed you have to reconcile.
An entity-owned pharmacy inside the same program. As an in-house pharmacy grows, contract pharmacy volume can shrink. A partner that sees both datasets in one place can help you evaluate how each contract pharmacy is being used and whether it continues to serve your patients and your program.
People, not just a portal. Ask who you call and what they bring you between audits. When something looks off, it should be one call to one team, not two vendors pointing fingers at each other.
A compliance trail an auditor can walk. Encounter to referral to dispense to replenishment, in one record. Test: if an auditor asked for the full story of your 340B program tomorrow, how many logins would it take to tell it?
A clear answer on ownership. Of the 48 TPA firms in the University of Minnesota study, eight were owned by private equity and six by vertically integrated players such as pharmacies, PBMs, and wholesalers. When a TPA is owned by a pharmacy chain or PBM, it's worth asking how that relationship might affect how your claims are handled.
For FQHCs, margins leave little room for leaks: community health centers averaged a negative 2.4% operating margin in 2024, according to NACHC's 2024 UDS Early Takeaways. For a lean team running both in-house and contract pharmacy, every extra system costs staff time.
For 340B-qualified hospitals, including critical access and rural hospitals, programs often span multiple registered child sites, and incorrect OPAIS records were the most common adverse finding in FY2025 HRSA audits. Every additional system is one more place a site or provider record can fall out of sync.
NuvemRx built the Unified Pharmacy Care Model so a safety-net provider doesn't have to assemble its program from parts. It's a closed-loop system with three components on one data layer in our Apollo platform:
Behind all three is Mission Control: a named team of NuvemRx experts working from a command center. In one example, Mission Control identified an FQHC running volume through pharmacies not designated to a clinic site in ESP. After realigning them, the health center's monthly savings rose by approximately $100,000. Results vary by organization.
Company-wide, the model has generated more than $2.6B in net 340B savings over 1.5B+ claims. None of our clients' HRSA audits in the past 10 years has resulted in a finding attributable to our services. And NuvemRx is not owned by a pharmacy chain or PBM.
One multi-entity rural health system ran NuReferrals side by side with a competing TPA's referral product for about a year: same system, same period. NuReferrals captured roughly $1.3M in net 340B savings. The other product captured about $40K. The health system reinvested those savings in free insulin, epinephrine, and inhaler programs and expanded rural access. Another health center left for a lower rate, then came back after an internal audit.
Consolidating isn't free. Interfaces get remapped and staff retrain. Termination windows vary from vendor to vendor, so the switch rarely happens all at once. Secure your historical audit records before you leave a current administrator, and expect an adjustment period while eligibility settings are tuned to capture what you should and nothing more. Ask any partner what they guarantee on data portability if you ever leave them.
The payoff is a program you can see all at once. Those savings were always meant to fund care, and seeing your whole program is how this year's savings become next year's pharmacist, extended hours, or a mobile clinic.
Want to see where your program is leaking? Let's look at your numbers together.
What is a single-vendor 340B TPA platform?
It's one partner and one system handling your 340B third-party administrator services end to end: eligibility, claims qualification, contract pharmacy administration, reporting, and audit support. The strongest versions also connect referral capture and entity-owned pharmacy operations to the same data layer.
Is a 340B TPA enough on its own?
Usually not. A TPA administers contract pharmacy claims, but referral capture, in-house pharmacy operations, and a growing list of manufacturer, HRSA, and CMS data requirements often sit with other vendors or with your staff. Each handoff is a place eligible savings can slip away.
What are the downsides of using separate vendors for 340B TPA services?
A different eligibility rulebook for each vendor, competing interests over limited contract pharmacy designations, heavier reconciliation for HRSA-recommended audits, stacked fees, and referral prescriptions lost between systems. The covered entity remains responsible for compliance regardless of how many vendors are involved, per HRSA.
How do I know if my 340B program needs a single platform?
Start with two questions. How many places does your eligibility logic live? If an auditor asked for the full story of your 340B program tomorrow, how many logins would it take to tell it? If either answer is more than one, or takes more than a minute, consolidation is worth a look.
Are there vendors that offer 340B-qualified hospitals a single platform for TPA services?
Yes. Several 340B TPA vendors offer single-platform administration for hospitals. What varies is scope: whether referral capture, entity-owned pharmacy operations, and compliance support run on the same data layer or sit beside it. NuvemRx's Unified Pharmacy Care Model combines TPA, pharmacy management, and referral capture on one data layer.
Is there one partner that can run an FQHC's 340B TPA, pharmacy operations, and referral capture?
Yes. NuvemRx runs all three for FQHCs and other safety-net providers through NuTPA, NuPharmacy, and NuReferrals, supported by a named Mission Control team. NuvemRx is 100% dedicated to safety-net providers.
Does hiring a 340B TPA transfer compliance responsibility?
No. HRSA's 2010 guidance says contract pharmacy arrangements do not lessen the covered entity's compliance duty, and HRSA recommends quarterly internal and annual independent audits of every contract pharmacy.
Not yet a client? Start a conversation with us below.
Bookmark this link for continually updated resources and insights to help pharmacy become the engine that drives expanded care for your community.
This article is general information for 340B covered entities and is not legal, tax, accounting, or financial advice. NuvemRx figures ($2.6B+ in net 340B savings and 1.5B+ claims) are company-wide, cumulative, and span all NuvemRx solutions. Single-client results describe one multi-entity rural health system's NuReferrals results over approximately one year and one FQHC's monthly savings after an ESP designation realignment; they are specific to those organizations' programs, payer mix, and pharmacy networks, and outcomes vary. Third-party figures reflect the sources cited as of their publication: TPA market data as of September 2023, NACHC survey data from 2022, NACHC UDS data for 2024, and Bluesight's analysis of FY2025 HRSA audits finalized at the time of its publication. Regulatory items (manufacturer data requirements, the HRSA rebate pilot, and the CMS repository) reflect their status as of October 2026 and may change. The fee example comes from a 2025 Senate HELP Committee report and describes one arrangement; fees differ by contract. Descriptions of TPA ownership and multi-vendor arrangements are general; specific arrangements differ by organization and by market. Whether a particular claim is 340B-eligible depends on your own program configuration and compliance review. Consult your own advisors, and confirm the requirements that apply to your organization.